Printer Friendly

Pfizer's Neurontin settlement.

Pfizer Inc. subsidiary Warner-Lambert has agreed to plead guilty and pay more than $430 million to settle charges that it improperly promoted off-label uses for its drug Neurontin. The drug was approved by the Food and Drug Administration in 1993 to treat epilepsy, but Warner-Lambert also promoted its use in bipolar disorder, amyotrophic lateral sclerosis, attention-deficit hyperactivity disorder, and migraine, among other conditions. "Warner-Lambert promoted Neurontin even when scientific studies had shown it was not effective," the Justice Department said in a statement. "The pharmaceutical company falsely promoted Neurontin as effective for treating bipolar disease, even when a scientific study demonstrated that a placebo worked as well or better than the drug." Warner-Lambert also misled doctors about Neurontin's use during supposed "independent medical education" events, the statement said. "In at least one instance, when unfavorable remarks were proposed by a speaker, Warner-Lambert offset the negative impact by planting people in the audience to ask questions highlighting the benefits of the drug."
COPYRIGHT 2004 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Policy & Practice
Author:Frieden, Joyce
Publication:Clinical Psychiatry News
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 1, 2004
Words:161
Previous Article:Mental health treatment common.
Next Article:Dangers of mixing drugs, alcohol.
Topics:


Related Articles
Lawsuits fault off-label use of Neurontin in suicide cases.
One lot of Neurontin recalled.
Pfizer pays $2bn in record fine.
Pfizer pays $2.3bn in record fine.
Pfizer to pay $2.3bn in record fine.
Pfizer to pay $2.3 bln to settle marketing charges.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters